In the past week, MBRX stock has gone down by -5.61%, with a monthly decline of -18.44% and a quarterly plunge of -22.21%. The volatility ratio for the week is 5.65%, and the volatility levels for the last 30 days are 4.24% for Moleculin Biotech Inc The simple moving average for the past 20 days is -12.57% for MBRX’s stock, with a -52.86% simple moving average for the past 200 days.
Is It Worth Investing in Moleculin Biotech Inc (NASDAQ: MBRX) Right Now?
Company’s 36-month beta value is 1.56.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MBRX is 14.01M, and currently, short sellers hold a 7.01% ratio of that floaft. The average trading volume of MBRX on June 04, 2025 was 473.46K shares.
MBRX) stock’s latest price update
Moleculin Biotech Inc (NASDAQ: MBRX)’s stock price has gone decline by -7.67 in comparison to its previous close of 0.91, however, the company has experienced a -5.61% decrease in its stock price over the last five trading days. seekingalpha.com reported 2025-05-14 that Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Jenene Thomas – IR, JTC Team, LLC Walter Klemp – Founder, President, CEO and Chairman Paul Waymack – Senior Chief Medical Officer Jonathan Foster – Executive VP & Chief Financial Officer Conference Call Participants Jonathan Aschoff – ROTH Capital Partners Jason McCarthy – Maxim Group Operator Good morning. Welcome to the Moleculin Biotech First Quarter 2025 Update Conference Call and Webcast.
Analysts’ Opinion of MBRX
Oppenheimer, on the other hand, stated in their research note that they expect to see MBRX reach a price target of $14. The rating they have provided for MBRX stocks is “Outperform” according to the report published on July 18th, 2022.
MBRX Trading at -12.14% from the 50-Day Moving Average
After a stumble in the market that brought MBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.86% of loss for the given period.
Stock Fundamentals for MBRX
The total capital return value is set at -1.84. Equity return is now at value -214.79, with -89.59 for asset returns.
Based on Moleculin Biotech Inc (MBRX), the company’s capital structure generated 0.89 points at debt to capital in total, while cash flow to debt ratio is standing at -66.59.
Currently, EBITDA for the company is -21.64 million with net debt to EBITDA at 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.35.
Conclusion
In a nutshell, Moleculin Biotech Inc (MBRX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
